期刊文献+

基于循证医学的我国基本药物目录遴选方法体系研究 被引量:3

Evidence-based research on the selection method system for China's essential medicine list
原文传递
导出
摘要 目的提出适合我国的基本药物目录遴选方法体系。方法收集并分析WHO、各国的基本药物目录遴选、调整技术文件以及循证医学、药物经济学评估、医保预算分析等相关研究文献,提出我国基本药物目录遴选的方法体系,并对该方法的可行性进行分析和实证。结果采用WHO所推荐的GRADE循证评价方法,对药物安全性、有效性进行评价,补充药物经济学评价,对药物经济效率全面评估,补充医保预算分析以确保基本药物的可支付性。该方法体系的理论已发展成熟,配套软件已开发成熟并应用。以浙江省糖尿病基本药物遴选为例进行实证,本方法具有较好的可行性。但医保等数据资料的共享尚存在壁垒,对科学遴选造成一定阻碍。结论目前基本药物遴选已具备较为完善的理论基础和方法工具,本研究提出的遴选方法体系具有一定的可操作性。建议决策者采用科学的方法遴选药物,促进数据资料的共享,从而提升基本药物目录的科学性和适用性。 Objective To find a selection method system appropriate for China's essential drug list. Methods Collection and analysis of technical paper literature on essential drug list developement, adjustment technical papers, and literature on evidence-based medicine, pharmacoeconomies evaluation, and medical insurance budget analysis from WHO and other countries. On such basis, a method system for selecting China's essential medicine list can be proposed, with its feasibility analyzed and demonstrated. Results The GRADE assessment proposed by WHO was used to evaluate the efficacy and safety of the drug ; the pharmacy economics evaluation is added to assess the economic efficiency ; these were aided by the pharmacoeconomics evaluation for a comprehensive evaluation of the pharmacoeeonomics of the drug in question, supplementing analysis of the medical insurance, and ensuring its affordahility of essential medicine so selected. The theory of this system is well developed, and supporting software ready for application. Examples in Zhejiang Province regarding essential medicine for diabetes have proved this method feasible. Data acquisition constitutes a major roadblock for scientific selection due to barriers against medical insurance data sharing. Conclusions Theoretic basis and method tools are fully available for essential medicine selection, and the selection method system as proposed in this study prove feasible to some extent. Decision makers are recommended to scientifically select the essential drugs, and to encourage data sharing, in order to make the list more scientific and pragmatic.
作者 张皓 顾淑燕 杨芊 郜林 甄雪梅 曾玉航 董恒进 Zhang Hao Gu Shuyan Yang Qian C.ao Lin Zhen Xuemei Zeng Yuhang Dong Hengjin(Center for Health Policy Studies, Zhefiang University School of Medicine, Hangzhou 310058, China)
出处 《中华医院管理杂志》 CSCD 北大核心 2017年第4期293-297,共5页 Chinese Journal of Hospital Administration
基金 基金项目:国家自然科学基金(面上项目)(71573229) 浙江省自然科学基金(LQ14G030009) 浙江省医药卫生科技计划(2014KYA055)
关键词 基本药物目录遴选 疾病负担评估 GRADE评价方法 药物经济学评估 医保预算分析 Essential medicine list selection Burden of disease assessment GRADE assessment Pharmacoeeonomics assessment Medical insurance budget analysis
  • 相关文献

参考文献6

二级参考文献147

  • 1何嗣英,吴勇群.二甲双胍和格列吡嗪对胰岛素敏感指数等的影响[J].海南医学院学报,2006,12(4):336-337. 被引量:3
  • 2刘立群,俞敏,钟节鸣,胡如英,陈雅萍,龚巍巍,韩晓军,严峻,葛琼,何升良,韩关根.浙江省居民营养与健康状况调查[J].浙江预防医学,2007,19(3):1-2. 被引量:26
  • 3卫生部,国家发改委等.关于建立国家基本药物制度的实施意见,2009-08-18.
  • 4中共中央,国务院.关于深化医药卫生体制改革的意见.北京:新华社.2009.http://news.xinhuanet.com/newscenter/2009-04/06/content_11138803.htm.
  • 5The Users' Guides to the Medical Literature: A Manual for Evidence- Based Clinical Practice (2nd ed). In: Guyatt G, Rennie D, Meade M, Cook D, editors. 2nd ed. New York, NY: McGraw-Hill; 2008.
  • 6Higgins JP, Altman D, Assessing the risk of bias in included studies, In: Higgins J, Green S, Editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Chichester, UK: John Wiley & Sons: 2008.
  • 7Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med, 2009, 361(20): 1963-1971.
  • 8Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials, lAMA, 2009, 302: 977-984.
  • 9Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ, 2008, 336(7644): 601-605.
  • 10Pocock SJ. When (not) to stop a clinical trial for benefit, lAMA, 2005, 294(17): 2228-2230.

共引文献105

同被引文献25

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部